drugset
drugset / Trial / NCT03748953

Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

NCT03748953 ↗

Phase 3 Completed 37 enrolled Millennium Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.

Timeline

Start
2019-01-24
Primary completion
2023-12-06
Completion
2023-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixazomib Unknown 4 mg Oral

Indications

plasma cell myeloma